Hochmair, MaximilianKiiskinen, UrpoD’yachkova, YuliaPuri, TarunWang, XuwenWolowacz, SorrelVickers, AdrianNadal, Ernest2025-07-152025-07-152025-06-031744-8301https://hdl.handle.net/2445/222240AimsSelpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methodsEfficacy and safety were compared using matching-adjusted indirect comparison.ResultsMedian progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade >= 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.ConclusionOutcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade >= 3 TRAEs.13 p.application/pdfengcc-by-nc-nd (c) Eli Lilly and Company, 2025http://creativecommons.org/licenses/by-nc-nd/3.0/es/Medicaments antineoplàsticsOncologiaAntineoplastic agentsOncologyinfo:eu-repo/semantics/article2025-07-10info:eu-repo/semantics/openAccess40458063